

# Giulia Morsica

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9522941/publications.pdf>

Version: 2024-02-01

52  
papers

856  
citations

687363

13  
h-index

501196

28  
g-index

52  
all docs

52  
docs citations

52  
times ranked

1263  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study. <i>Hepatology</i> , 2006, 43, 556-562.	7.3	216
2	Occult hepatitis B virus infection in a Cohort of HIV-positive patients: Correlation with hepatitis C virus coinfection, virological and immunological features. <i>Infection</i> , 2009, 37, 445-449.	4.7	56
3	Polymerase chain reaction for <i>Toxoplasma gondii</i> DNA in the cerebrospinal fluid of AIDS patients with focal brain lesions. <i>Aids</i> , 1994, 8, 1691-1694.	2.2	54
4	Detection of hepatitis C virus genomic sequences in the cerebrospinal fluid of HIV-infected patients. , 1997, 53, 252-254.		42
5	Pretreatment of Chronic Active Hepatitis C in Patients Coinfected With HIV and Hepatitis C Virus Reduces the Hepatotoxicity Associated With Subsequent Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2003, 33, 146-152.	2.1	40
6	Resistance Mechanisms in Hepatitis C Virus: implications for Direct-Acting Antiviral Use. <i>Drugs</i> , 2017, 77, 1043-1055.	10.9	40
7	Ribavirin therapy for chronic hepatitis C does not modify HIV viral load in HIV-1 positive patients under antiretroviral treatment. <i>Aids</i> , 2000, 14, 1656-1658.	2.2	38
8	Detection of Hepatitis C Mutants With Natural Resistance to NS3/4A Protease Inhibitors in HIV/HCV-Coinfected Individuals Treated With Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 106-108.	2.1	28
9	Hepatitis C virus populations in the plasma, peripheral blood mononuclear cells and cerebrospinal fluid of HIV/hepatitis C virus-co-infected patients. <i>Aids</i> , 2005, 19, S151-S165.	2.2	27
10	Viral Interference Between Hepatitis B, C, and D Viruses in Dual and Triple Infections in HIV-Positive Patients. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2009, 51, 574-581.	2.1	23
11	Design and Characterization of a Peptide Mimotope of the HIV-1 gp120 Bridging Sheet. <i>International Journal of Molecular Sciences</i> , 2012, 13, 5674-5699.	4.1	22
12	A liquid chromatography-tandem mass spectrometry method for simultaneous determination of simeprevir, daclatasvir, sofosbuvir, and GS-331007 applied to a retrospective clinical pharmacological study. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1120, 1-7.	2.3	22
13	Frequency of Natural Resistance within NS5a Replication Complex Domain in Hepatitis C Genotypes 1a, 1b: Possible Implication of Subtype-Specific Resistance Selection in Multiple Direct Acting Antivirals Drugs Combination Treatment. <i>Viruses</i> , 2016, 8, 91.	3.3	20
14	Prevalence of wild-type in NS5A-PKR protein kinase binding domain in HCV-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2002, 36, 116-122.	3.7	16
15	GB Virus C and Hepatitis C Virus Infection in Patients with Mixed Cryoglobulinemia. <i>Annals of Internal Medicine</i> , 2000, 133, 394.	3.9	15
16	Hepatitis C virus (HCV) coinfection in a cohort of HIV positive long-term non-progressors: Possible protective effect of infecting HCV genotype on HIV disease progression. <i>Journal of Clinical Virology</i> , 2007, 39, 82-86.	3.1	13
17	Molecular characterization of occult and overt hepatitis B (HBV) infection in an HIV-infected person with reactivation of HBV after antiretroviral treatment interruption. <i>Infection</i> , 2010, 38, 417-421.	4.7	13
18	Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption. <i>Infection</i> , 2011, 39, 121-126.	4.7	12

#	ARTICLE	IF	CITATIONS
19	Resistance analysis and treatment outcomes in hepatitis C virus genotype 3a infected patients within the Italian network VIRONET. <i>Liver International</i> , 2021, 41, 1802-1814.	3.9	12
20	Evolution of the E2 region of hepatitis C virus in an infant infected by mother-to-infant transmission. <i>Journal of Medical Virology</i> , 2001, 64, 476-481.	5.0	11
21	Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study. <i>PLoS ONE</i> , 2017, 12, e0184128.	2.5	11
22	Non-invasive fibrosis biomarkers "APRI" and "Forns" are associated with liver stiffness in HIV-monoinfected patients receiving antiretroviral drugs. <i>Liver International</i> , 2013, 33, 1113-1120.	3.9	10
23	Molecular epidemiology of HIV-1 infection in immigrant population in northern Italy. <i>Epidemiology and Infection</i> , 2020, 148, e19.	2.1	10
24	Virological pattern of hepatitis B infection in an HIV-positive man with fatal fulminant hepatitis B: a case report. <i>Journal of Medical Case Reports</i> , 2009, 3, 110.	0.8	9
25	Geographic Distribution of HCV-GT3 Subtypes and Naturally Occurring Resistance Associated Substitutions. <i>Viruses</i> , 2019, 11, 148.	3.3	9
26	Evolution of hepatitis C virus non-structural 5A gene in the progression of liver disease to hepatocellular carcinoma. <i>Liver International</i> , 2007, 27, 1126-1133.	3.9	8
27	Dynamic of Mixed HCV Infection in Plasma and PBMC of HIV/HCV Patients Under Treatment With Peg-IFN/Ribavirin. <i>Medicine (United States)</i> , 2015, 94, e1876.	1.0	8
28	Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohort. <i>Hepatology International</i> , 2020, 14, 362-372.	4.2	8
29	HIV-1 recombinant forms in immigrants regularly residing in Milan, northern Italy. <i>Infection</i> , 2020, 48, 553-558.	4.7	8
30	Effect of increasing dose of interferon on the evolution of hepatitis C virus 1b quasispecies. , 2000, 60, 133-138.		7
31	Occurrence of hepatocellular carcinoma in HIV/HCV co-infected patients treated with direct-acting antivirals. <i>Journal of Hepatology</i> , 2017, 67, 415-417.	3.7	7
32	Hepatitis C virus infection in blood donors with indeterminate results in second-generation recombinant immunoblot assay. <i>Transfusion</i> , 1994, 34, 555-556.	1.6	6
33	NS3 protease resistance-associated substitutions in liver tissue and plasma samples from patients infected by hepatitis C virus genotype 1A or 1B. <i>Archives of Virology</i> , 2017, 162, 2271-2277.	2.1	6
34	Brief Report: Outcome of Acute Hepatitis B Virus Infection in HIV-1 Infected Patients: Possible Factors Associated With Resolution or Chronicity. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2019, 82, 175-180.	2.1	6
35	Natural polymorphisms in the resistance associated sites of HCV-G1 NS5B domain and correlation with geographic origin of HCV isolates. <i>Virology Journal</i> , 2018, 15, 144.	3.4	4
36	Hepatic safety profile of darunavir with low-dose ritonavir (DRV/r) in HIV/HCV coinfecting and HIV monoinfected patients. <i>New Microbiologica</i> , 2011, 34, 317-21.	0.1	4

#	ARTICLE	IF	CITATIONS
37	A Prospective Italian Study on Baseline NS3 and NS5A Resistance to Direct-Acting Antivirals in a Real-World Setting of HIV-1/HCV Coinfected Patients and Association with Treatment Outcome. <i>Viruses</i> , 2020, 12, 269.	3.3	3
38	Reversion of naturally occurring high-level resistance mutations to NS3 protease inhibitors in two treatment-naïve individuals infected with hepatitis C virus. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 1448-1450.	3.0	2
39	Sustained virological response after ten days of triple anti-hepatitis C virus (HCV) therapy with telaprevir plus pegylated interferon and ribavirin in an HIV/HCV co-infected cirrhotic woman. <i>International Journal of Infectious Diseases</i> , 2014, 29, 100-102.	3.3	2
40	Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort. <i>Digestive and Liver Disease</i> , 2021, 53, 1603-1609.	0.9	2
41	Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort. <i>Antiviral Therapy</i> , 2020, 25, 73-81.	1.0	2
42	Levels of Alpha-Fetoprotein and Association with Mortality in Hepatocellular Carcinoma of HIV-1-Infected Patients. <i>Journal of Oncology</i> , 2022, 2022, 1-10.	1.3	2
43	Compartmentalization of Resistance-Associated Substitutions in HIV/HCV-Infected Patients: Possible Correlation with Infecting HCV Genotype. <i>Viruses</i> , 2021, 13, 1486.	3.3	1
44	Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV. <i>PLoS ONE</i> , 2022, 17, e0262917.	2.5	1
45	Prevalence of wild-type in interferon sensitivity determining region (ISDR) of hepatitis C virus in HIV-1 positive patients infected with HCV genotype 3A non responders to anti-HCV treatment. <i>Journal of Hepatology</i> , 2002, 36, 71.	3.7	0
46	Prevalence of a 660 amino acid substitution in the PePHD region of HCV-E2 protein in hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2002, 36, 80.	3.7	0
47	HBV/HCV coinfection: viral genomic profile of dominant virus. <i>Journal of Hepatology</i> , 2002, 36, 222.	3.7	0
48	Comparison of IFN- $\alpha$ 2b with or without ribavirin for treatment of chronic hepatitis C in HIV-positive patients infected with hepatitis C virus genotype 3a. <i>Aids</i> , 2004, 18, 1080-1082.	2.2	0
49	The appropriate method of evaluating the dynamics of hepatitis B virus in patients receiving antiviral treatment: the other side of the coin. <i>Aids</i> , 2005, 19, 1933-1934.	2.2	0
50	THU-117-Evaluation of risk factors associated with failure to a first-line NS5A-containing regimen in HCV-infected patients naïve to direct acting antivirals: Particular focus on natural resistance. <i>Journal of Hepatology</i> , 2019, 70, e209-e210.	3.7	0
51	SAT-404-Discordant NS5a but not NS3 RASs profile in liver and plasma compartments of HIV/HCV genotype 1a/4d infected patients. <i>Journal of Hepatology</i> , 2019, 70, e812.	3.7	0
52	Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naïve to anti-HCV protease inhibitors. <i>New Microbiologica</i> , 2017, 40, 53-55.	0.1	0